Table 1.
Listed are classic neurotrophins that have been evaluated in animal models related to ALS. Given are the respective animal model, the application mode of the factor, and the outcome of the experiment.
| Model | Treatment (animal/group) | Outcomes | Reference | |
|---|---|---|---|---|
| BDNF | Axotomy, rat | Gel foam, 5 μg (n = 9) | +30% MNs survival | Sendtner et al. (1992a) |
| Axotomy, rat | s.c. injection, 5 mg/kg (n = 4) | +30% MNs survival | Yan et al. (1992) | |
| Axotomy, rat | Viral (n = 4) | +15% MNs survival | Gimenez y Ribotta et al. (1997) | |
| Excitotoxic lesion, mice | Viral (n = 12) | Neuroprotection | Bemelmans et al. (2006) | |
| Woobler mice | s.c. injection 5 mg/kg 3 times a week (n = 10) | +Motor function +Enervation |
Ikeda et al. (1995) | |
| SOD-1G93A mice | Ex vivo, presympt.(n = 18) | No benefit | Park et al. (2009) | |
| CNTF | Axotomy, rat | Gel foam, 5 μg (n = 4) | +55% MNs survival | Sendtner et al. (1990) |
| pmn mice | Ex vivo (n = 8) | +MNs +Motor functions +Survival |
Sendtner et al. (1992b) | |
| GDNF | Axotomy, rat | Viral (n = 9) | +20% MNs survival | Gimenez y Ribotta et al. (1997) |
| SOD-1G93A mice | Ex vivo, presympt. (n = 16) | +Motor functions +MNs +Atrophy |
Mohajeri et al. (1999) | |
| SOD-1G93A mice | Viral, presympt. (n = 17) | +Motor functions +12% survival |
Acsadi et al. (2002) | |
| SOD-1G93A rats | Ex vivo, presympt. (n = 9) | +MNs 0 NMJs | Suzuki et al. (2007) | |
| SOD-1G93A mice | Transgenic, presympt. (n = 31) | +Motor functions +MNs +11% survival |
Li et al. (2007) | |
| SOD-1G93A mice | Ex vivo, presympt. (n = 46) | +MNs, 0 survival | Park et al. (2009) |
+: significant benefit; 0: no significant benefit; s.c.: subcutaneous; i.p.: intraperitoneal; presympt.: presymptomatic.